Some of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through ...

Hollywood needed “A Minecraft Movie” to be a hit, and it delivered in its opening weekend, significantly narrowing this year's box office deficit.

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the federal government’s Medicare program. The Centers for Medicare and ...

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

The Los Angeles Times filed a lawsuit Thursday against the city of L.A., accusing officials of unlawfully withholding and deleting the mayor’s text messages and other public ...

The newest generation of GLP-1 drugs has delivered life-changing benefits to patients managing diabetes, obesity, heart ...

Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug market. Analysts expect the pill to be as ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...

Excellent clinical trial data caused Viking Therapeutics stock to shoot higher in 2024. Eli Lilly markets a diabetes and weight-management drug that is growing sales by leaps and bounds.

The days of cheaper alternatives to popular weight-loss drugs like Wegovy and Zepbound are over for some Long Islanders and are numbered for others, pharmacists and compounding industry groups say.

As the popularity of Ozempic, Victoza, Wegovy and other GLP-1 agonists have continued to increase, ... More so have restrictions on insurance coverage for many of them. (Photo by: Michael Siluk ...